Lung Cancer Vaccines: Pipeline, Strategies and Clinical
Article by Bharatbook
Lung Cancer Vaccines: Pipeline, Strategies and Clinical - Health - Cancer
Search by Author, Title or Content
Article ContentAuthor NameArticle Title
Home
Submit Articles
Author Guidelines
Publisher Guidelines
Content Feeds
RSS Feeds
FAQ
Contact Us
Bharatbook added a new report on " Lung Cancer Vaccines: Pipeline, Strategies and Clinical " which gives an overview, Demand, Supply Trends and industry analysis reports.
This report provides a comprehensive review of 42 candidate vaccines that are being evaluated for the treatment of covering pipeline, disease-targeting strategies and clinical findings. These vaccines are directed at 24 antigens or antigen combinations.
Globally, the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that lung cancer-care costs (in 2006) were the third highest of all cancers, while indirect costs (2005) were higher than for any other cancer.
Patient needs and the high burden of drive the development of new therapies. While improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies that build on the capabilities of existing approaches, are urgently required. Today, developments continue to be made in drug treatments for in chemotherapy, new drug combinations and targeted molecules. In particular, advances are being seen in the field of immunotherapy; in the development of new therapeutic antibodies and therapeutic vaccines.
This Report
This report (see brochure) provides a comprehensive review of vaccines and reviews R&D and clinical developments in the treatment of as the primary indication, as well as studies that are evaluating alongside other cancers.
Today, more than 40 candidate vaccines are in development or being evaluated for the treatment of most of which are already in clinical trials. This field is also showing substantial innovation and 24 different antigen/multiple antigen targeting strategies are being investigated. For the purpose of this report, multiple antigen targeting approaches have been treated as single strategies. This report gives an overview of the status and clinical findings of these candidate vaccines, and gives developmental and market-related perspectives in this rapidly developing field.
Key content:
? Late-stage (Phases 2/3, 3 and Approved, n = 5) pipeline vaccines and companies
? Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 37) pipeline vaccines and companies
? Other (mainly antibody related, n=6) candidate therapies in the development pipeline for targeting Phase 1, 1/2 and 2
? Antigens/antigen combinations being targeted by vaccines from preclinical through to Phase 3 and Approved
? Descriptions of clinical trials (patients and numbers, conditions, treatments, regimens, Phase 1-3) of therapeutic vaccines being evaluated for the treatment.
? Summaries of clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses) reported following clinical trials (Phase 1-3) of vaccines being evaluated for the treatment of lung cancer
? Commercial partnerships and collaborations on pipeline therapeutic vaccines
? Drug combination strategies in the evaluation of therapeutic vaccines for the targeting.
? A comprehensive listing of salient details of clinical trials of therapeutic vaccines being evaluated for the treatment.
? Technical and market insights and perspectives in the development and clinical evaluation of therapeutic vaccines for the treatment.
? Competitive and market-related information
Tables
Global incidence and mortality from 2008
NSCLC survival rates, according to cancer stage
1.3a Five-year relative cancer survival rates in the USA for white males
1.3b Five-year relative cancer survival rates in the USA for white females
US national expenditure on different cancers (2006)
US lost productivity due to different cancer types in the US, 2005
2.1 Approved/late-stage vaccines for the treatment of lung cancer
3.1 Early-stage vaccines being developed or evaluated for the treatment of lung cancer/other cancers
4.1 Other (largely antibody-related) therapies being developed or evaluated for the treatment of other cancers
5.1 Approved/late-stage candidate vaccines being developed for the treatment of lung cancer
5.2 Early-stage candidate vaccines being developed or evaluated for lung/other cancers
Other (primarily antibody-related) therapies in development or being evaluated for lung cancer/other cancers
Approved/candidate vaccines for the treatment of for other cancers
Other candidate therapies (primarily antibody-related) for the treatment of for other cancers
NSCLC survival rates, according to cancer stage
Figures
3.1 Early-staged pipeline vaccines for the treatment of lung cancer or other cancers
5.1 Early-stage pipeline vaccines in development or being evaluated for lung/other cancers
5.2 Other (primarily antibody-related) early-stage candidate therapies in development or being evaluated for other cancers
5.3 Organisations developing or evaluating lung cancer therapeutic vaccines
5.4 Clinical trials of vaccines for the treatment of other cancers, involving single or combination agents
For more information kindly visit :
http://www.bharatbook.com/detail.asp?id=213743&rt=Lung-Cancer-Vaccines-Pipeline-Strategies-and-Clinical.html
Or
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668 / +91 22 27579438
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: http://www.bharatbook.com
Bharat Book Bureau, the leading market research information aggregator provides company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.
Use and distribution of this article is subject to our Publisher Guidelines
whereby the original author's information and copyright must be included.
Bharatbook
RSS Feed
Report Article
Publish Article
Print Article
Add to Favorites
Article Directory
About
FAQ
Contact Us
Advanced Search
Privacy Statement
Disclaimer
GoArticles.com � 2012, All Rights Reserved.
Bharat Book Bureau, the leading market research information aggregator provides company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.
Use and distribution of this article is subject to our Publisher Guidelines
whereby the original author's information and copyright must be included.
| Speech therapy | | VATplus Aids You With Novel Lingo . WeWeOur CompanyOur Staff | Suggestions to Buy Backlinks for Nearby Search Oomph | VATplus Displays Completely New Approaches . . . WeWeOur CompanyOur | The 9 MostFanatical Brides Cheats... And The Way To Utilize | vertigo-exercises | You Can Make Money With Article Marketing By Following These | All a Load of Yoga Mats
No comments:
Post a Comment